Cancer Immunology – News and Features

Researchers have discovered that a novel combination therapy promotes cancer cell death and tumor regression in pancreatic cancer.

A new graphene oxide platform that mimics the interactions between immune cells could stimulate CAR T cells to reproduce, making CAR T-cell therapy more effective.

Natural killer T cells could be used to produce antitumor activity in solid tumors.

Three patients are in “safe, deep remission” after receiving a CRISPR-Cas9-modified cell therapy for autoimmune disease treatment, according to a new published study in Cell.

Engineered E.coli bacteria can move into tumors and indue potent immune responses, acting as a GPS for immunotherapies.

UCLA researchers developed a non-invasive imaging method using 89Zr-TLX250 to detect clear-cell renal cell carcinoma. This technique demonstrated high sensitivity (85.5%) and specificity (87.0%), effectively identifying cancer in small renal masses.

A new treatment has been proposed for immunotherapy-resistant brain metastases, with a biomarker identified that can predict cases in which it should be used.

An unexpected role of estrogen in fueling the growth of breast and other cancers has been discovered.

Researchers at the University of Geneva developed CAR T cells targeting the glioblastoma marker PTPRZ1, showing efficacy against tumors. These cells not only attack marked tumor cells but also eliminate others through a bystander effect.

A study shows that the CAR-T cells of long-term survivors of acute lymphoblastic leukemia exhibit a distinct type 2 immune response, linked to increased remission rates. A second study indicates that modifying IL-4 can enhance T cell metabolism.